The new rapid spreader variant B 1.1.7 has undergone 23 mutations and may be too much to handle for the available vaccines. Read more »
Vaccines may or may work; one needs to observe physical distancing, cough/sneeze etiquettes, face mask, and lead a low social activity life. Read more »
Relaxing penal provisions under the Companies Act may encourage scams and misuse of the loopholes that are not so apparent now. Read more »
Here are the positive movements that will drive growth after a dismal year that saw Covid-19 denting economic prospects. Read more »
The US, India, Brazil and Russia are examples of what can go wrong when assumptions drive policies -- not science or data. Read more »
Given the fragmented nature of climate finance architecture, more guidance will be needed by poor countries to navigate this landscape. Read more »
A natural infection may not be enough to protect one for the rest of his/her life -- one needs to take a vaccine to be sure. Read more »
Persisting inflationary pressure both from food and core prices poses further downside risk for the post Covid-19 economy. Read more »
Equitable access to Covid vaccines to protect healthcare workers and other at-risk people is a crucial requirement for mitigating pain caused by the pandemic. Read more »
At least 68 candidate vaccines are in various stages of human trials – 38 in phase I, 17 in phase II and 13 in phase III. Read more »